Licensing · Global (LMICs) · Announced 26 Oct 2026
Janssen Sciences Ireland → Biocon
Biocon signed a licence with Janssen Sciences Ireland allowing it to commercialise its Stelara biosimilar Yesintek (ustekinumab) in nine more markets, including Brazil, Mexico and Kazakhstan, with immediate effect; terms undisclosed.
Parties: Janssen Sciences Ireland (Johnson & Johnson) (Ireland) → Biocon (India)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Nine additional markets: Brazil, Mexico, Kazakhstan, China, Hong Kong, South Korea, Israel, Australia, New Zealand
- Therapeutic area
- Immunology / Inflammation
- Asset
- ustekinumab
- Announced
- 26 Oct 2026
Our analysis
Why this matters
On 26 October 2026 Biocon told the Indian stock exchanges it had signed a licence agreement with Janssen Sciences Ireland, part of Johnson & Johnson, covering Yesintek (ustekinumab-kfce), its biosimilar to Stelara. The licence adds nine markets — Brazil, Mexico, Kazakhstan, China, Hong Kong, South Korea, Israel, Australia and New Zealand — and takes effect immediately. Launches in each country remain subject to regulatory approval. No financial terms were disclosed.
The deal builds on earlier Biocon–Janssen agreements that set entry dates in the US, Europe, the UK, Canada and Japan. It comes as Stelara sales fall sharply; Citeline notes J&J's Q3 2026 results showed global Stelara revenue down 54%.
The full analysis is free to read with a work email on this page.
Source: Citeline Generics Bulletin